Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.

ABSTRACT: The remarkable advances in next-generation sequencing technology have enabled the wide usage of sequencing as a clinical tool. To promote the advance of precision oncology for breast cancer in China, here we report a large-scale prospective clinical sequencing program using the Fudan-BC panel, and comprehensively analyze the clinical and genomic characteristics of Chinese breast cancer. The mutational landscape of 1,134 breast cancers reveals that the most significant differences between Chinese and Western patients occurred in the hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer subtype. Mutations in p53 and Hippo signaling pathways are more prevalent, and 2 mutually exclusive and 9 co-occurring patterns exist among 9 oncogenic pathways in our coh

SUBMITTER: Lang GT 

PROVIDER: S-EPMC7656255 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature